CivicaScript will initially develop and manufacture six to ten medicines for which there is currently not enough market competition to drive down price.

As membership grows and funding increases, the number of medications will grow.

In addition, CivicaScript is working with sister company Civica, Inc. and numerous partners to bring affordable insulin to market in 2024.